Harris Reacts Following Second Delay of Insulin/EpiPen Savings Rule

Statement

WASHINGTON, DC: Congressman Andy Harris, M.D., today reacted to the Biden Administration's second delay of a Trump era executive action which would lower the consumer cost of insulin and EpiPens in community health centers. The Administration is now planning to delay the cost-saving rule until July 20th, four months after their the previous delayed launch date of March 22nd, and a full six months after the initial implementation date the Trump Administration had established. Dr. Harris had previously criticized the initial delay by President Biden to keep costs high for some of our most vulnerable.

Congressman Harris issued the following statement:

"Once again, the Biden Administration has chosen to delay significant cost-saving policy measures which would make insulin and EpiPens much more easily affordable to those who utilize our community health centers for care. The policy in question was not political, yet this political delay will do nothing other than harm individuals relying on these medications and keep drug prices high."

Maryland's First Congressional District is served by 5 community health centers, with over 100,000 patients and millions of dollars in leveraged federal funding each year.

Source